- Pharmaceutical Products
- Products By Brand Name
- Products By Dosage Form
- Products By Generic Name
- Products By Therapeutic Class
Find a product
Find Generic
Arnivas
Sacubitril and Valsartan
Description:
Arnivas is a combination of Sacubitril, a neprilysin inhibitor and Valsartan, an angiotensin II receptor blocker, indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class II-IV) and reduced left ventricular ejection fraction.
Arnivas is a combination of Sacubitril, a neprilysin inhibitor and Valsartan, an angiotensin II receptor blocker, indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class II-IV) and reduced left ventricular ejection fraction.
Indications:
Arnivas is indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class II-IV) and reduced left ventricular ejection fraction.
Arnivas is indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class II-IV) and reduced left ventricular ejection fraction.
Mode of Action:
Arnivas is the combination of Sacubitril and Valsartan of which Valsartan inhibits the effects of angiotensin II receptor, thereby prevents the deleterious cardiac effects of RAAS activation and Sacubitril enhances vasoactive peptides such as natriuretic peptides by inhibiting neprilysin.
Arnivas is the combination of Sacubitril and Valsartan of which Valsartan inhibits the effects of angiotensin II receptor, thereby prevents the deleterious cardiac effects of RAAS activation and Sacubitril enhances vasoactive peptides such as natriuretic peptides by inhibiting neprilysin.
Other Brands From Same Therapeutic Class
